home / stock / cdmop / cdmop news

CDMOP News and Press, Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock From 09/07/22

Stock Information
Company Name: Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock
Stock Symbol: CDMOP
Market: NASDAQ
Website: avidbio.com
Menu
CDMOP CDMOP Quote CDMOP Short CDMOP News CDMOP Articles CDMOP Message Board
Get CDMOP Alerts

News, Short Squeeze, Breakout and More Instantly...
CDMOP - Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology a...
CDMOP - Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments

-- Recorded First Quarter Revenue of $36.7 Million -- -- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $157 Million -- -- Facilities and Capabilities Expansions in Mammalian and Cell and Gene Therapy Businesses ...

CDMOP - Avid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell Business

TUSTIN, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology a...

CDMOP - Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022

TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today a...
CDMOP - Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments

-- Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respectively -- -- Signed $44 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $153 Million -- -- New Cell and Gene Therapy Analytical and Process...

CDMOP - Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022

TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today a...

CDMOP - Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility

AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility Build-Out of Facility’s CGMP Manufacturing Suites Continues, Expected to Come Online in Mid-Calendar 2023 TUSTIN, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Avid Bioservic...
CDMOP - Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business

New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost Approximately $6 Million with Completion Anticipated by End of Calendar 2022 TUSTIN, C...

CDMOP - Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today ...

CDMOP - Avid Bioservices' (CDMO) CEO Nick Green on Q3 2022 Results - Earnings Call Transcript

Avid Bioservices (CDMO) Q3 2022 Earnings Conference Call March 8, 2022 4:30 PM ET Company Participants Tim Brons – Executive Vice President of Vida Strategic Partners Nick Green – President and Chief Executive Officer Dan Hart – Chief Financial Officer Matt Kwietniak ...
Previous 10 Next 10